gsk medical affairs jobs near london
Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. 10. 1. Prescription Patterns Among Newly Diagnosed Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome): Evidence from a Managed Care Database in the United States. POSTER: ENGOT-EN6/NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin-Paclitaxel Versus Placebo + Carboplatin-Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer (EC), 6. Impact of State Residence on Adult Vaccination Uptake: A Multilevel Modeling Approach. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. Patients? POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial, 2. 4. PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: The DREAMM-2 Study: What Were the Effects of Belantamab Mafodotin in Patients With Multiple Myeloma and Reduced Kidney Function? Ferguson GT, Brown N, Compton C, et al. Insights From Allergy Practice (Poster No. Get notified about new Gsk Medical Affairs jobs in United States. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines, 1. 2. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER, Bintrafusp Alfa Bifunctional TGF-? PUBLICATION ONLY: Real-world treatment patterns of patients initiating third-line therapy in relapsed or refractory multiple myeloma in Europe, 14. Analysis of a Composite Endpoint of Exacerbation and Early Study Treatment Withdrawal in Symptomatic Patients With COPD Free of Inhaled Corticosteroids: A Post Hoc Analysis of the EMAX Trial. Pitrez P, Bruselle G, Yorganc?o?lu A, et al. Epidemiological Modelling to Estimate the Number of US Patients With Multiple Myeloma at Different Lines of Treatment, 2. The response(s) are not intended to offer recommendations for administering this product in a manner inconsistent with its approved labeling. Paclitaxel Versus Placebo + Carboplatin?Paclitaxel in Recurrent or Primary Advanced Endometrial Cancer, 7. Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. Bogart M, Bancroft T, Rothnie K, et al. Characteristics and Inpatient Outcomes of Hospitalized Patients with COVID-19 ? Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. POSTER: Subramanian S, et al. 2. 1. Presentation with Audio: A First-in-Human Phase I Study of the OX40 Agonist GSK3174998 (GSK998) +/- Pembrolizumab in Patients (Pts) With Selected Advanced Solid Tumors (ENGAGE-1), 3. 1. DREAMM-4: Evaluating Safety and Clinical Activity of Belantamab Mafodotin in Combination With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 14. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). 4. Open-label, single-arm study evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment in patients with localized, HER2-negative, BRCA-mutant breast cancer, 1. CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. P699; Abstract A1814]. DREAMM-2: Single-Agent Belantamab Mafodotin (Belamaf) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) ? Modeling of short-acting beta agonist (SABA) use: effect of symptom control in patients with moderate-severe asthma requiring rescue medication. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in DREAMM-2 Study: 13-Month Follow-Up, 4. Therapeutic ASCEND-ID: Daprodustat is non-inferior to darbepoetin alfa in treating anemia in incident dialysis patients. Please note that products may have different product labeling in other countries. Singh AK, et al. The estimated total pay for a Medical Affairs at GSK is $206,808 per year. Desrosiers M, Diamant Z, Castelnuovo P, et al. signaling and HMGA2, a potential biomarker for bintrafusp alfa in triple negative breast cancer, 3. Can Recombinant Zoster Vaccine Administration Decrease the Use of HZ-Related Pain Medication Across Randomized Controlled Studies? ViiV (GSK) Global Medical Affairs Director: GSK PLC: London, England: 32K-85K: Medical Director, Healthcare Solutions - Respiratory: GSK PLC: Brentford, England: . POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. Asthma control among the treated U.S. asthma population in Practice Fusion?s Electronic Medical Record Research Database, 2015-2018. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448). Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 4. POSTER: Factors Affecting PARP Inhibitor Use as Maintenance Treatment in Platinum-Sensitive Recurrent Ovarian Cancer, 2. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-. Poster No. 1-Year Outcomes by Prior Therapies, 6. Rescue Medication Use as an Indicator of Symptom Burden in Patients With COPD: A Post Hoc Analysis of the EMAX Trial. P786; Abstract A5624]. Int J Mol Sci. Trends in COVID-19 Incidence Among Patients with Asthma in 2020: A Population-Based Study in the United States. GSK 4.2 Brentford Delivering the field medical and scientific engagement plan. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. Rapoport AP, Stadtmauer EA, Binder-Scholl GK, et al. Corbridge T, Casale T, Germain G, et al. A Population Study. Rates of Major Events in Untreated Patients Diagnosed ?With Anemia of CKD in France?? CAPTAIN Study: Simultaneous Step-up to High Dose Fluticasone Furoate and Addition of Umeclidinium for the Treatment of Inadequately Controlled Asthma. Onze 340), 1. Cobolimab is a humanized TIM-3 antagonist immunoglobulin G4 (IgG4) mAb being investigated as a monotherapy and in combination with dostarlimab and TSR-033 in advanced solid tumors, including melanoma, NSCLC, and colorectal cancer. ASCEND-ID: Daprodustat is Non-Inferior to Darbepoetin Alfa in Treating Anemia in Incident Dialysis Patients, 2. Obeid D, Bansal S, Brown N, et al. For roles at the vice president level and above, we expect an ethnically diverse representation of at least 30% by 2025. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. Prevalence of asthma and severe asthma in patients affiliated to the Hospital Italiano Medical Care Program in Buenos Aires, Argentina. Efficacy of Mepolizumab Stratified by Baseline Blood Eosinophil Count, 9. [Poster No. POSTER: Physicians? P372; Abstract A6482]. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study ? All rights reserved. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 4. The Impact of Comorbidities and Clinical Characteristics on Real-World Mepolizumab Effectiveness in Patients With Severe Asthma: Results From the REALITI-A Study. [Oral presentation available here; Abstract A4212]. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol compared with tiotropium monotherapy in chronic obstructive pulmonary disease: a post hoc analysis by airflow limitation. Mepolizumab Treatment Leads to Clinical Asthma Remission in Patients with Severe Eosinophilic Asthma: Results from the Real-World REDES Study. Continuity of Care Assessment Within a Vertically Integrated Care Management Organization Before and After COPD-related Exacerbations. 1090; Abstract A3325]. in Patients with Asthma: A Post-Marketing Surveillance (PMS) in Korea. 1. Trade marks are owned by or licensed to the GSK group of companies. 1. 1465. (Poster No. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. A phase I study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open-label single-agent study in subjects with non-Hodgkin?s lymphoma (NHL), 3. ORAL PRESENTATION: OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis, 2. Slade D, Ray R, Moretz C, et al. receptor II (TGF-?RII or TGF-? POSTER: Demographics and survival outcomes in patients (pts) with advanced or recurrent (A/R) endometrial cancer (EC) in the English real-world (RW) setting, 1.POSTER: Real world data of Niraparib in platinum sensitive relapsed ovarian cancer: a multicenter experience of the MITO group (Presentation Is Not Available Due to Copyright), 1. Our market sites can be reached by visiting our location selector. MOONSTONE: A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab in Patients With Platinum Resistant Ovarian Cancer (TiP), 5. GSK?S SCIENTIFIC ACTIVITIES AT IDWEEK 2020, 2. Blood. O?Connor BP, Raman VS, Erikson LD, et al. . Symptom Burden in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy. P1481. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in the United States: A Population-Based Study. 3. Immunotherapy. 8. Baseline Characteristics in Patients with Eosinophilic Granulomatosis with Polyangiitis in the U.S. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Provision of unlicensed medicines for unmet medical needs, Chemical Manufacturing and Controls (CMC), Medicine Development and Supply (MDS), Work experience, placements and internships, Manufacturing Operations, Quality & Logistics, Fraudulent internet recruitment activities. Fiore. Time-Dependent Covariate Analysis of Hemoglobin Values ?on Risk of MACE in the ASCEND Trials. Bring your unwanted, unused, and expired medicines to the 24th@DEAHQQ's National Prescription Drug#TakeBackDayy between 10AM - 2PM. GSK Solid Tumor Oncology Account Manager; Long Island East, NY Long Island-Queens 30d+ $160K-$216K Per Year (Employer est.) Angevin E, Barnette MS, Bauer TM, et al. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, 26. GSK is investigating a PI3K inhibitor, GSK2636771, in combination with enzalutamide, in PTEN-deficient metastatic castration-resistant prostate cancer (mCRPC). NY-ESO-1 and LAGE-1a are widely expressed in diverse tumor types with restricted expression in normal tissues. Trademarks are owned by or licensed to the GSK group of companies. [Oral presentation available here; Abstract A4211]. Dransfield MT, Halpin DMG, Han MK, et al. POSTER: Survival outcomes for dostarlimab and real-world (RW) treatment (tx) paradigms in post-platinum patients (pts) with advanced/recurrent (A/R) endometrial cancer (EC): The GARNET trial vs an external control arm from the Flatiron Health database, 9. 5. POSTER: BET Inhibitor Molibresib for the Treatment of Advanced Solid Tumors: Final Results From an Open-Label Phase I/II study, 20. POSTER: RSVPreF3 OA Candidate Vaccine Safety Presentation. Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. and LAGE-1a?specific affinity-enhanced TCRs. [Poster No. ABSTRACT ONLY: Post-hoc analysis from two phase I/II NY-ESO-1-TCR T-cell therapy clinical trials in patients with advanced sarcoma (SS or MRCLS) demonstrates response across a range of NY-ESO-1 expression, 3. Pavord ID, Fowler A, Kerstjens HA, et al. Nat Med. POSTER: Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial (Presentation Is Not Available Due to Copyright), 4.POSTER: Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma (Presentation Posted With Permission), 5.POSTER: Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Included in the Compassionate Use or the Expanded Access Program. PO0487, 1. Today's top 149 Gsk Medical Affairs jobs in United States. Further details on cookies and how to object to their placement can be found in our Cookie Policy. Singh T et al. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. Jha V, et al. Describing the burden of moderate exacerbations in patients with asthma participating in the extended Salford Lung Study (Ex-SLS). peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). The results included enhanced training for recruiting managers, a thorough review of job postings and more direction on the channels used to reach and attract candidates. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, 4. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. 712; Abstract A1827]. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. perspective on the burden of Hypereosinophilic Syndrome. P1444. Poster No. 6. 3. POSTER: ENGOT-OV44/FIRST Study: A Randomized, Double-Blind, Adaptive, Phase 3 Study of Platinum-Based Chemotherapy (CT) Dostarlimab Followed by Niraparib Dostarlimab Maintenance as First-Line (1L) Treatment of Stage 3 or 4 OC, 2. 2. P1501. Hahn B, Bogart M, Silver J, et al. P0017. 3. [Poster No. Fedoriw A, Rajapurkar SR, O?Brien S, et al. Exploring Use of Regular ICS/LABA Dosing in Moderate to Severe Asthma Among Physicians: Results from the Asthma Patients? Exacerbation Reduction in Patients Based Upon Baseline Eosinophil Counts and FEV1 Reversibility. Strobel MJ, Alves D, Roufosse F, et al. Singh AK, et al. 518; Abstract A4579]. Cho E-Y, Cho J-E, Jang S-H, et al. Terrier B, Jayne D, Hellmich B, et al. Initiating Mepolizumab. 714; Abstract A4267]. Poster No. The Relationship Between Overall Survival (OS), Progression-Free Survival (PFS), and Objective Response Rate (ORR) in Immune Checkpoint Inhibitor Clinical Trials of Head and Neck Squamous Cell Carcinoma (HNSCC): A Systematic Review and Meta-analysis, 10. GSK plc. 2. Vogelmeier CF, Kerwin EM, Naya IP, et al. 2015;16(9):21138-21152. Tim-3 and its role in regulating anti-tumor immunity. peRspectives on the burden and managemENT of asthma studies (APPaRENT 1 & 2). Patient-reported symptom outcomes from COMET-ICE, a phase III study of sotrovimab for early treatment of non-hospitalized patients with COVID-19. New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and cancer-testis antigen 2 (LAGE-1a) are immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor ? NY-ESO-1 and LAGE-1a are highly homologous immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. BCMA is essential for the survival of long-lived bone marrow plasma cells. [Poster No. Benefits of Initiating Single-Inhaler Triple Therapy (SITT) with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Multiple-Inhaler Triple Therapy (MITT) Among Medicare Advantage with Part D Beneficiaries with Chronic Obstructive Pulmonary Disease (COPD). 817; Abstract A4306]. Lu E, et al. P1483. POSTER: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. POSTER: VOCAL (Views of Ovarian Cancer patients-how maintenance therapy Affects their Lives) study: patient preference for treatment formulation and administration (IGCS ENCORE), 6. 4. NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. ORAL PRESENTATION: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis (Encore), 1. POSTER: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor(Encore), 1. 54 jobs. 1. Brain Metastases in Primary Ovarian Cancer: Real-world Data, 1. Mepolizumab Reduces Exacerbations and Improves Health-Related Quality of Life in Patients With Severe Asthma and Nasal Polyps, Sinusitis, or Allergic Rhinitis. This information does not take the place of talking with your doctor. 5. POSTER: Synergistic Effects of Low Dose Belantamab Mafodotin in Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study, 4. [Poster No. #ppswgg#myoldmedss#safedisposallz, Real conversations generate impactful change. 61), 1. Communication with Patients/Parents on MenB Vaccination for Older Adolescents and Young Adults. Dr. John Mascarenhas, a hematologist oncologist, explains what this condition is, how it presents and how it is diagnosed. ORAL PRESENTATION: MOMENTUM: Phase 3 Randomized Study of Momelotinib (MB) versus Danazol (DAN) in Symptomatic and Anemia Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 2. McCormack E, Adams KJ, Hassan NJ, et al. Triple checkpoint blockade targeting PD-1, TIM-3, and LAG-3 improves T cell reinvigoration and antitumor efficacy over single and double combinations, 1. 2015;21(8):914-921. 1466. Findings From the Macunama Study, 5. ORAL PRESENTATION: Final overall survival and long-term safety in the ENGOT-OV16/NOVA phase III trial of niraparib in patients with recurrent ovarian cancer, 2. POSTER: Immune-Related Endpoints in Patients with Advanced or Recurrent Endometrial Cancer Treated with Dostarlimab in the GARNET Study, 4. POSTER: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 5. Front Oncol. Associations between haemoglobin values and rate of changes with MACE in the ASCEND-ND randomised clinical trial. Impact of the COVID-19 Pandemic on Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in the United States: A Population-Based Study. 2. DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Pomalidomide and Dexamethasone (B-Pd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 10. ein Mensch und keine Maschine sind. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. 2015;21(8):914-921. Consider joining our contingent talent community for contract opportunities. 1. Andrews LP, Marciscano AE, Drake CG, Vignali DAA. (Poster No. POSTER: Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy? . 2. 1-800-FDA-1088 You may also report suspected adverse reactions to the FDA at ur employees and our values are at the heart of everything we do. Fowler A, Kerstjens HAM, Bailes Z, et al.
